• Ribosome biogenesis as a therapeutic target against cancer: a study on the verification role of RPL5/RPL11/5S rRNA p53 in the development and treatment of Diamond–Blackfan Anaemia (DBA) and function of the c-MyC genes in ribosome biogenesis in the development of colorectal cancer.
  • The role of nutrients in diabetes, cancer, obesity and ageing, through mTORC1/S6K1 signalling: a study on the role of amino acids and glucose in tumour generation and resistance to insulin through mTORC1/S6K1 and the molecular components through which biguanides suppress mTORC1 signalling.
  • The role of mTORC1 as a signalling pathway for hepatocellular carcinoma: identification of the subsequent effectors of TORC1 through which tumorigenesis and the mechanisms of resistance to RAD001/BEZ235 are measured.
  • A study of the molecular mechanisms responsible for E2F1 function in cancer: identification of the signalling pathways responsible for mTOR activation through E2F1 and the role of E2F1 in hepatocellular carcinoma.

S6 kinase 1 plays a key role in mitochondrial morphology and cellular energy flow.

Tran Q, Jung JH, Park J, Lee H, Hong Y, Cho H, Kim M, Park S, Kwon SH, Kim SH, Thomas G, Kim KP, Cho MH

CELLULAR SIGNALLING (ISSN/ISBN: 08986568)

2018

Mitochondrial Complex I Activity Is Required for Maximal Autophagy

Thomas H., Zhang Y., Stefely J., Veiga S., Thomas G., Kozma S., Mercer C.

CELL REPORTS. (ISSN/ISBN: 22111247). 24(9): 2404-2417.E8

2018

Ribosome biogenesis in cancer: New players and therapeutic avenues

Pelletier J., Thomas G., Volarevi S.

NATURE REVIEWS CANCER (ISSN/ISBN: 1474175X). 18 (1) : 51-63

2018

Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR.

Veiga SR, Ge X, Mercer CA, Hernández-Álvarez MI, Thomas HE, Hernandez-Losa J, Ramón Y Cajal S, Zorzano A, Thomas G, Kozma SC

CLINICAL CANCER RESEARCH (ISSN/ISBN: 10780432)

2018

Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR

Veiga, S.; Ge, X.; Mercer, C.; Hernandez-Alvarez, M.; Thomas, H.; Hernandez-Losa, J.; Cajal, S. R. Y.; Zorzano, A.; Thomas, G.; Kozma, S.;

ANNALS OF ONCOLOGY. (ISSN/ISBN: 09237534). 29

2018

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

Wise-Draper T., Moorthy G., Salkeni M., Karim N., Thomas H., Mercer C., Beg M., O’Gara S., Olowokure O., Fathallah H., Kozma S., Thomas G., Rixe O., Desai P., Morris J.

TARGETED ONCOLOGY (ISSN/ISBN: 17762596). 12 (3) : 1-10

2017

Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signaling and malignant features in vitro and in vivo

Sesé M., Fuentes P., Esteve-Codina A., Béjar E., McGrail K., Thomas G., Aasen T., Ramón y Cajal S.

ONCOTARGET. (ISSN/ISBN: 19492553). 8(70): 114856-114876

2017

EPRS is a critical mTORC1-S6K1 effector that influences adiposity in mice

Arif, Abul; Terenzi, Fulvia; Potdar, Alka A.; Jia, Jie; Sacks, Jessica; China, Arnab; Halawani, Dalia; Vasu, Kommireddy; Li, Xiaoxia; Brown, J. Mark; Chen, Jie; Kozma, Sara C.; Thomas, George; Fox, Paul L.;

NATURE (ISSN/ISBN: 00280836). 542 (7641) : 357-361

2017

A novel 40S complex involved in the regulation of 5 ' TOP mRNA stability: A role in mTOR hyperactivated tumors?

Gentilella, Antonio; Moron-Duran, Francisco D.; Rocha, Guilherme Z.; Riano-Canalias, Ferran; Pelletier, Joffrey; Tauler, Albert; Kozma, Sara; Thomas, George;

CANCER RESEARCH (ISSN/ISBN: 00085472). 77

2017

Characterization of the pre-ribosomal complex, which mediates the p53 Impaired Ribosome Biogenesis Checkpoint (IRBC)

Menoyo, Sandra; Gentilella, Antonio; Thomas, George;

CANCER RESEARCH (ISSN/ISBN: 00085472). 77

2017

See full list

RESTRICTING OBESITY: ANTI-S6K1 THERAPY

Kozma, Sara Catherine (Investigador principal (IP))

Ref.: 201617-10

Entitat finançadora:
  • FUNDACIÓ LA MARATÓ DE TV3

2017-02-28 - 2020-02-27

Desvelando la eficacia terapéutica de los inhibidores de mTOR en CHC

Kozma, Sara Catherine (Investigador principal (IP))

Ref.: PI16/01762

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2017-01-01 - 2019-12-31

AYUDAS JUAN DE LA CIERVA - INCORPORACION 2015

Mauvezin, Caroline (Investigador principal (IP))

Ref.: IJCI-2015-24716

Entitat finançadora:
  • MINISTERIO DE EDUCACIÓN Y CIENCIA

2017-01-01 - 2018-12-31

AYUDAS JUAN DE LA CIERVA - FORMACION 2014

PELLETIER, JOFFREY (Investigador principal (IP))

Ref.: FJCI-2014-20422

Entitat finançadora:
  • MINISTERIO DE EDUCACIÓN Y CIENCIA

2016-05-18 - 2018-05-17

Assessment of the Efficacy of Combining RAD001 and MLN0128, in Human Hepatocellular Carcinoma (HCC).

Thomas, George (Participante); Kozma, Sara Catherine (Otros)

Ref.: PCRS-2015-101126

Entitat finançadora:
  • TAKEDA PHARMACEUTICALS

Examine the efficacy of combining RAD001 and metformin with MLN0128 for treating human hepatocellular carcinoma HCC

Kozma, Sara Catherine (Investigador principal (IP))

Ref.: RAD001

Entitat finançadora:
  • TAKEDA

Understanding the Molecular Mechanisms Controlling Nucleolar Surveillance in Disease.

Thomas, George (Otros)

Ref.: 1102609

Entitat finançadora:
  • NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL.

2016-01-01 - 2019-01-01

AYUDAS PARA CONTRATOS PREDOCTORALES PARA LA FORMACIÓN DE DOCTORES 2015

Thomas, George (Investigador principal (IP))

Ref.: BES-2015-075840

Entitat finançadora:
  • MINISTERIO DE EDUCACIÓN Y CIENCIA

2015-12-01 - 2019-11-30

Autophagy, mTOR inhibitors in hepatocellular carcinoma

Kozma, Sara Catherine (Otros)

Ref.: 1R21CA191814

2015-06-01 - 2017-05-31

New therapeutic strategies for resistant colorectal cancer

Ruiz Fernandez, Marta (Participante)

Entitat finançadora:
  • FUNDACIÓ AECC INVESTIGACIÓN CONTRA EL CÁNCER

2015-04-01 - 2020-03-31

See full list

Study of the molecular mechanisms responsible for E2F1-induced mTORC1 activation

Tauler Girona, Albert (Director) Doctorando: Nathalie Meo Evoli

2014

Study of the molecular mechanism responsible for E2F1-induced mTORC1 activation

Tauler Girona, Albert (Director) Doctorando: Nathalie Meo-Evoli

2014

Efecte de la inhibició de les histona desacetilases I d'inductors de p53 en línies cel.lulars de neuroblastoma humà.

Tauler Girona, Albert (Director) Doctorando: Consatanza Cortés Crignola

2014

Study of the apoptotic pathway induced by E2F1 in neuronal cells

Tauler Girona, Albert (Director) Doctorando: Lilia Espada

2011

Estudio del papel de E2F1 en el crecimiento celular y la partipación de la Ser4o3 en la regulación de la actividad transcripcional de E2F1

Tauler Girona, Albert (Director) Doctorando: Sebastian Real

2009

Apoptotic action of E2F1 required GSK3 activity in PC12 cells

Tauler Girona, Albert (Director) Doctorando: Basavaraj Udapudi

2008

Regulation of E2F1 transcription factor by glycogen synthase kinase-3-beta

Tauler Girona, Albert (Director) Doctorando: Gisela Garcia Alvarez

2005

See full list

Dr Thomas and Dr Kozma are renowned for their discoveries related to the mTORC1/S6K1/4E-BP1 signalling pathway, having obtained FDA approval for the use of rapamycin in different types of cancer and to launch clinical trials based on the use of specific mTOR dual inhibitors.

Dr Tauler has worked extensively on the glycolytic pathway and its control through mitogenic signals. Some of his studies on PF2K bifunctionality are included in leading Biochemistry textbooks